These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34786633)

  • 21. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials.
    Dicembrini I; Cosentino C; Monami M; Mannucci E; Pala L
    Acta Diabetol; 2021 Apr; 58(4):401-410. PubMed ID: 32789691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between glucose measurement parameters of continuous flash monitoring and HbA1c. Real life experience in Asturias.
    Pujante Alarcón P; Alonso Felgueroso C; Ares Blanco J; Morales Sánchez P; Lambert Goitia C; Rodríguez Escobedo R; Rodríguez Rodero S; Delgado Alvarez E; Menéndez Torre EL
    Endocrinol Diabetes Nutr (Engl Ed); 2022; 69(7):493-499. PubMed ID: 36028448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID Study.
    Blevins T; Lane W; Rodbard D; Sindelar D; Fan L; Ellinor K; Ilag L; Ly T; Johnson J
    Diabetes Technol Ther; 2021 Jan; 23(1):51-58. PubMed ID: 32631081
    [No Abstract]   [Full Text] [Related]  

  • 24. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
    Arunachalum S; Velado K; Vigersky RA; Cordero TL
    J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life 24-week changes in glycemic parameters among European users of flash glucose monitoring with type 1 and 2 diabetes and different levels of glycemic control.
    Lameijer A; Bakker JJ; Kao K; Xu Y; Gans ROB; Bilo HJG; Dunn TC; van Dijk PR
    Diabetes Res Clin Pract; 2023 Jul; 201():110735. PubMed ID: 37276981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scans per day as predictors of optimal glycemic control in people with type 1 diabetes mellitus using flash glucose monitoring: what number of scans per day should raise a red flag?
    Sebastian-Valles F; Martínez-Alfonso J; Arranz Martin JA; Jiménez-Díaz J; Hernando Alday I; Navas-Moreno V; Armenta Joya T; Fandiño García MDM; Román Gómez GL; Lander Lobariñas LE; Martinez de Icaya P; Sampedro-Nuñez MA; Martínez-Vizacaíno V; Marazuela M
    Acta Diabetol; 2024 Mar; 61(3):343-350. PubMed ID: 37930420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous subcutaneous insulin infusion does not correspond with pregnancy outcomes despite better glycemic control as compared to multiple daily injections in type 1 diabetes - Significance of pregnancy planning and prepregnancy HbA1c.
    Żurawska-Kliś M; Kosiński M; Kuchnicka A; Rurka M; Hałucha J; Wójcik M; Cypryk K
    Diabetes Res Clin Pract; 2021 Feb; 172():108628. PubMed ID: 33358970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
    Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
    Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of use of specific features of subcutaneous insulin infusion systems and their relationship to metabolic control in patients with type 1 diabetes.
    Quirós C; Patrascioiu I; Giménez M; Vinagre I; Vidal M; Jansà M; Conget I
    Endocrinol Nutr; 2014; 61(6):318-22. PubMed ID: 24533929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy.
    Heptulla RA; Allen HF; Gross TM; Reiter EO
    Pediatr Diabetes; 2004 Mar; 5(1):10-5. PubMed ID: 15043684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Experience of Using Telemedicine for the Management of Patients Using Continuous Subcutaneous Insulin Infusion in a Highly Complex Latin American Hospital.
    Guzman GE; Escobar MF; Arias-Valderrama O; Guerra MA; Martínez V
    Int J Environ Res Public Health; 2023 May; 20(9):. PubMed ID: 37174237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey.
    Roze S; Smith-Palmer J; de Portu S; Özdemir Saltik AZ; Akgül T; Deyneli O
    Diabetes Technol Ther; 2019 Dec; 21(12):727-735. PubMed ID: 31509715
    [No Abstract]   [Full Text] [Related]  

  • 34. Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injections.
    Rodbard D; Jovanovic L; Garg SK
    Diabetes Technol Ther; 2009 Dec; 11(12):757-65. PubMed ID: 20001676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporal Trends for Diabetes Management and Glycemic Control Between 2010 and 2019 in Korean Children and Adolescents with Type 1 Diabetes.
    Choe J; Won SH; Choe Y; Park SH; Lee YJ; Lee J; Lee YA; Lim HH; Yoo JH; Lee SY; Kim EY; Shin CH; Kim JH
    Diabetes Technol Ther; 2022 Mar; 24(3):201-211. PubMed ID: 34704794
    [No Abstract]   [Full Text] [Related]  

  • 36. Factors associated with glycemic control in adult type 1 diabetes patients treated with insulin pump therapy.
    Matejko B; Skupien J; Mrozińska S; Grzanka M; Cyganek K; Kiec-Wilk B; Malecki MT; Klupa T
    Endocrine; 2015 Feb; 48(1):164-9. PubMed ID: 24798448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of metabolic control and use of flash glucose monitoring systems in a cohort of pediatric, adolescents, and adults patients with Type 1 diabetes.
    Bahíllo-Curieses MP; Díaz-Soto G; Vidueira-Martínez AM; Torres-Ballester I; Gómez-Hoyos E; de Luis-Román D
    Endocrine; 2021 Jul; 73(1):47-51. PubMed ID: 33754313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of flash glucose monitoring on glycemic control varies with the age and residual β-cell function of patients with type 1 diabetes mellitus.
    Zhang L; Xu Y; Jiang X; Wu J; Liu F; Fan L; Li X; Yin G; Yang L
    J Diabetes Investig; 2022 Mar; 13(3):552-559. PubMed ID: 34637185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical Approach to Using Trend Arrows on Real-Time Continuous Glucose Monitoring System in Type 1 Diabetes Adolescents Living Camp Setting Treated With Multiple Daily Injection or Continuous Subcutaneous Insulin Infusion Insulin Therapy.
    Bassi M; Minuto N; Fichera G; Rebora C; Parodi A; Natoli V; Pontillo L; Buccianti M; d'Annunzio G; Maghnie M
    J Diabetes Sci Technol; 2021 Sep; 15(5):1098-1103. PubMed ID: 32552001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus.
    Alemzadeh R; Palma-Sisto P; Holzum M; Parton E; Kicher J
    Diabetes Technol Ther; 2007 Aug; 9(4):339-47. PubMed ID: 17705689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.